obesity drug news today glp-1 2025 sep 30 Dozens of new drugs are coming: these are the ones to watch Nutritional priorities to support GLP-1
Description
Beyond obesity and type 2 diabetes, the therapeutic potential of GLP-1 RAs extends to a range of conditions such as cardiovascular disease, liver disease, neurodegenerative disease, and substance abuse disorders
3.4 GLP-1 improves cognition by protecting neurons Some recent studies have shown that GLP-1RAs acted on the nervous system and provides neuroprotection
Therefore, the development of novel drug delivery systemswhether by enhancing BRB penetration or through direct ocular targeting (e.g., long-acting intravitreal formulations)is a critical and rate-limiting step for the clinical translation of these agents
However, all individuals who were enrolled in the study did have to have an elevated BMI greater than 30 and had to have moderate to severe OSA
J Diabetes Investig 1:823 Samms RJ, Coghlan MP, Sloop KW (2020) How may gip enhance the therapeutic efficacy of GLP-1
